Literature DB >> 24481706

1,25(OH)₂D₃ induces a mineralization defect and loss of bone mineral density in genetic hypercalciuric stone-forming rats.

Adeline H Ng1, Kevin K Frick, Nancy S Krieger, John R Asplin, Madison Cohen-McFarlane, Christopher D Culbertson, Kelly Kyker-Snowman, Marc D Grynpas, David A Bushinsky.   

Abstract

Genetic hypercalciuric stone-forming (GHS) rats, bred to maximize urine (u) calcium (Ca) excretion, demonstrate increased intestinal Ca absorption, increased bone Ca resorption, and reduced renal Ca reabsorption, all leading to elevated uCa compared to the parental Sprague-Dawley (SD) rats. GHS rats have increased numbers of vitamin D receptors (VDRs) at each site, with normal levels of 1,25(OH)₂D₃ (1,25D), suggesting their VDR is undersaturated with 1,25D. We have shown that 1,25D induces a greater increase in uCa in GHS than SD rats. To examine the effect of the increased VDR on the osseous response to 1,25D, we fed GHS and SD rats an ample Ca diet and injected either 1,25D [low dose (LD) 12.5 or high dose (HD) 25 ng/100 g body weight/day] or vehicle (veh) daily for 16 days. Femoral areal bone mineral density (aBMD, by DEXA) was decreased in GHS+LD and GHS+HD relative to GHS+veh, while there was no effect on SD. Vertebral aBMD was lower in GHS compared to SD and further decreased in GHS+HD. Both femoral and L6 vertebral volumetric BMD (by μCT) were lower in GHS and further reduced by HD. Histomorphometry indicated a decreased osteoclast number in GHS+HD compared to GHS+veh or SD+HD. In tibiae, GHS+HD trabecular thickness and number increased, with a 12-fold increase in osteoid volume but only a threefold increase in bone volume. Bone formation rate was decreased in GHS+HD relative to GHS+veh, confirming the mineralization defect. The loss of BMD and the mineralization defect in GHS rats contribute to increased hypercalciuria; if these effects persist, they would result in decreased bone strength, making these bones more fracture-prone. The enhanced effect of 1,25D in GHS rats indicates that the increased VDRs are biologically active.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24481706      PMCID: PMC4276134          DOI: 10.1007/s00223-014-9838-7

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  47 in total

Review 1.  Calcium absorption across epithelia.

Authors:  Joost G J Hoenderop; Bernd Nilius; René J M Bindels
Journal:  Physiol Rev       Date:  2005-01       Impact factor: 37.312

2.  Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats.

Authors:  D A Bushinsky; K J Neumann; J Asplin; N S Krieger
Journal:  Kidney Int       Date:  1999-01       Impact factor: 10.612

3.  Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast.

Authors:  Paul A Baldock; Gethin P Thomas; Jason M Hodge; Sara Uk Baker; Uwe Dressel; Peter D O'Loughlin; Geoffrey C Nicholson; Kathy H Briffa; John A Eisman; Edith M Gardiner
Journal:  J Bone Miner Res       Date:  2006-10       Impact factor: 6.741

Review 4.  Genetic hypercalciuria.

Authors:  Orson W Moe; Olivier Bonny
Journal:  J Am Soc Nephrol       Date:  2005-02-02       Impact factor: 10.121

5.  Regulation of renal calcium receptor gene expression by 1,25-dihydroxyvitamin D3 in genetic hypercalciuric stone-forming rats.

Authors:  Jim J Yao; Shaochun Bai; Alexander J Karnauskas; David A Bushinsky; Murray J Favus
Journal:  J Am Soc Nephrol       Date:  2005-03-23       Impact factor: 10.121

6.  Isolation and confirmation of a calcium excretion quantitative trait locus on chromosome 1 in genetic hypercalciuric stone-forming congenic rats.

Authors:  Richard R Hoopes; Frank A Middleton; Saunak Sen; Paul A Hueber; Robert Reid; David A Bushinsky; Steven J Scheinman
Journal:  J Am Soc Nephrol       Date:  2006-04-12       Impact factor: 10.121

7.  Thiazides reduce brushite, but not calcium oxalate, supersaturation, and stone formation in genetic hypercalciuric stone-forming rats.

Authors:  David A Bushinsky; John R Asplin
Journal:  J Am Soc Nephrol       Date:  2005-01-12       Impact factor: 10.121

8.  Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone-forming rats.

Authors:  Alexander J Karnauskas; Johannes P T M van Leeuwen; Gert-Jan C M van den Bemd; Paru P Kathpalia; Hector F DeLuca; David A Bushinsky; Murray J Favus
Journal:  J Bone Miner Res       Date:  2004-11-29       Impact factor: 6.741

9.  Normal vitamin D receptor concentration and responsiveness to 1, 25-dihydroxyvitamin D3 in skin fibroblasts from patients with absorptive hypercalciuria.

Authors:  J E Zerwekh; B Y Reed; H J Heller; G B González; M R Haussler; C Y Pak
Journal:  Miner Electrolyte Metab       Date:  1998

10.  Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats.

Authors:  D A Bushinsky; K Laplante; J R Asplin
Journal:  Kidney Int       Date:  2006-05       Impact factor: 10.612

View more
  3 in total

1.  Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats.

Authors:  Nancy S Krieger; John R Asplin; Ignacio Granja; Felix M Ramos; Courtney Flotteron; Luojing Chen; Tong Tong Wu; Marc D Grynpas; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2019-05-17       Impact factor: 10.121

2.  Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria.

Authors:  Nancy S Krieger; John R Asplin; Kevin K Frick; Ignacio Granja; Christopher D Culbertson; Adeline Ng; Marc D Grynpas; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

3.  Histochemical examination of the effects of high-dose 1,25(OH)2D3 on bone remodeling in young growing rats.

Authors:  Jing Sun; Bao Sun; Wei Wang; Xiuchun Han; Hongrui Liu; Juan Du; Wei Feng; Bo Liu; Norio Amizuka; Minqi Li
Journal:  J Mol Histol       Date:  2016-06-02       Impact factor: 2.611

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.